Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Visa Europe signs deal with Validsoft
http://www.visaeurope.com/en/newsroom/news/latest.aspx
NYTimes - "CT Scans Cut Lung Cancer Deaths"
Finally some positive press...!!
According to a recent government-financed NIH study, its been determined that annual CT scans of current and former heavy smokers reduced their risk of death from lung cancer by 20% and that these cancer doctors predict that the study's results would soon "lead to widespread use of CT scans" for current smokers who have a 1 in 10 chance of contracting lung cancer.
http://www.nytimes.com/2010/11/05/health/research/05cancer.html
The article goes on to say that the federal Medicare program "will soon reconsider paying for these CT lung screens" instead of the patients having to pay for the scans themselves, and that these CT scans also "helped to detect other life-threatening diseases besides lung cancer."
And according to the American Heart Association, there are currently an estimated 24.8 million men and 21.1 million women in the United States who are smokers (that's unbelievable, and very sad), and we know that lung cancer claims about 157,000 lives each year (just terrible).
I believe these recent findings will benefit RDNT in a meaningful way, and could create significant revenue opportunities going forward.
As we know, RDNT is one of the largest multi-modality imaging companies in the country with one of the largest fleets of imaging equipment, including CT scans. Should the federal government begin to pay for annual CT scans for these current and former smokers, RDNT could not be better positioned to capitalize on these new recent developments IMHO.
As the study suggests, at least for lung cancer, "spending more on tests saves lives."
What a great opportunity for RDNT and its shareholders.
Gov't Grants of $374,000 (surprise, surprise)
NGNM to receive almost $0.4 million in government grants this month for the work its doing on new cancer diagnostics tests...what a pleasant surprise!!
I give credit to management for even submitting the applications, and glad to see them thinking outside the box a little bit. The $0.4 million will definitely help the company's cash flows this quarter.
And nice job on the ICLK...
These guys are really killing it, though i think its unfortunate that CEO Mathews is moving on. Having said that, the company did post very strong third quarter results as well as raised Q4 guidance, and the stocks got a lot of momentum behind it right now as all the analysts revise their models and raise estimates.
Just remember though that revenue growth is expected to really decelerate in 2011 with revenue estimates next year of around $121 million, or just a 25% increase over 2010 as compared to the 80% YoY increase in 2010 and 146% increase in 2009 (I think revenues grew almost 240% in 2008). Which means, if true, I think the stock could lose a lot of its momentum investors as next year unfolds, and some of the shine off the stock.
As for INUV, they too just posted very strong third quarter results IMHO with revs up 53% YoY to $14.3 million, gross profits up 63% YoY (good leverage), expanding profit margins, a smaller operating loss and a nice jump in EBITDA to $1.2 million as compared to just $52k a year ago.
Management continues to divest themselves of the few remaining non-core assets, with just one small remaining property left to sell, and seems very well positioned to now exploit their platform and growth initiatives.
Again, if investors think ICLK is undervalued and trading at around 1.5x sales, INUV is difinitely worth a very hard look down here at just 0.6x sales.
I added to my position just today.
NGNM – worth a look...
I hope GHDX shareholders are feeling pretty good about GE's announcement last week to purhcase CLRT for over 5x sales, I know I am. Another small cancer diagnostics company worth taking a hard look at is NGNM.
The company just reported solid third quarter results, with revenue growth of 19% YoY and volume growth of 29% YoY. I think management did a great job on the conference call and seem to be making all of the right moves. With much of the heavy lifting now behind the company, business should begin to improve each quarter going forward, and probably one of the reasons why management was comfortable enough to provide 2011 estimates. NGNM now expects 2011 revenues to be in the range of $41-45 million, which would imply a 25-30% increase in sales next year.
Clearly, the business has bottomed and the business model has reached critical mass.
At 5x 2011 sales of $41 million, NGNM would fetch between $4-5 per share from a strategic buyer.
So at $1.10, the stock appears to be way undervalued and a great opportunity for any small-cap investor, and I still believe NGNM is going to be a big winner, even more than ever, after listening to the third quarter conference call.
NGNM – Strong Buy at $1.10
ENZ shareholders may also want to pay attention to NGNM, another small cancer diagnostics company.
NGNM just reported solid third quarter results, with revenue growth of 19% YoY and volume growth of 29% YoY. I think management did a great job on the conference call and seem to be making all of the right moves. With much of the heavy lifting now behind the company, business should begin to improve each quarter going forward, and probably one of the reasons why management was comfortable enough to provide 2011 estimates. NGNM now expects 2011 revenues to be in the range of $41-45 million, which would imply a 25-30% increase in sales next year, and an increase from the 15-18% expected revenue growth in 2010.
Clearly, the business has bottomed and the business model has reached critical mass.
NGNM at $1.10 is way undervalued and great opportunity for any small-cap investor, and I still believe NGNM is going to be a big winner, even more than ever, after listening to the third quarter conference call.
NGNM – Solid Third Quarter Results
For all you happy CLRT investors, I still think everyone should give a long hard look at NGNM, and listen to the most recent third quarter conference call.
The company just reported solid third quarter results, with revenue growth of 19% YoY and volume growth of 29% YoY. I think management did a great job on the conference call and seem to be making all of the right moves. With much of the heavy lifting now behind the company, business should begin to improve each quarter going forward, and probably one of the reasons why management was comfortable enough to provide 2011 estimates. NGNM now expects 2011 revenues to be in the range of $41-45 million, which would imply a 25-30% increase in sales next year, and an increase from the 15-18% expected revenue growth in 2010.
Clearly, the business has bottomed and the business model has reached critical mass.
NGNM at $1.10 is way undervalued and great opportunity for any small-cap investor, and I still believe NGNM is going to be a big winner, even more than ever, after listening to the third quarter conference call.
NGNM – Solid Third Quarter Results
NGNM just reported solid third quarter results, with revenue growth of 19% YoY and volume growth of 29% YoY. I think management did a great job on the conference call and seem to be making all of the right moves. With much of the heavy lifting now behind the company, business should begin to improve each quarter going forward, and probably one of the reasons why management was comfortable enough to provide 2011 estimates. NGNM now expects 2011 revenues to be in the range of $41-45 million, which would imply a 25-30% increase in sales next year, and an increase from the 15-18% expected revenue growth in 2010.
Clearly, the business has bottomed and the business model has reached critical mass.
NGNM at $1.10 is way undervalued and a great opportunity for any small-cap investor, and I still believe NGNM is going to be a big winner, even more than ever, after listening to the third quarter conference call.
CLRT Investors - NGNM worth paying attention to at $1.10
Congrats to all those investors in CLRT and BioMedReports for writing up the company last month.
NGNM is another cancer diagnostics company that i've been following and worth a real hard look at these levels. They've got a great management team lead by CEO Van Oort, the former COO of Quest Diagnostics and Covance who wrote his own $500,000 check to join the company back in March 2009. Abbott Labs (ABT) also invested $4.8 million in July 2009, at $1.36 per share, and is a 10% shareholder.
NGNM continues to growth the business and on pace to generate around $35 million in sales this year. With new cancer tests coming to market and a great relationship with ABT, NGNM is undervalued and well positioned.
At 5x sales, which is what GE just paid for CLRT, NGNM would fetch $4-5 per share.
NGNM – Strong Buy at $1
I like NGNM right here at a $1 per share. They've got a great management team, growing revenues, new cancer tests coming to market, great access to IP through their partnership with ABT and the infrastructure is already build and ready to handle a bigger business.
NGNM is going to be a big winner.
What's the "bear" story on RDNT
Timothy, great call last month on RDNT. It looks like the stock is down around 25% since your short-bias post.
I was just wondering if you could share your "bear" case with everyone. I think that would be helpful.
Thanks
Sound Analysis - Also watch INUV
I agree that ValueClick and others in the industry/sector currently trade at multiples between 2-3 times price/sales and that ICLK is currently trading below the group, at roughly 1.6 times price/sales. I like CEO Mathews very much, have been following him for a couple of years now and think he's done an outstanding job.
For those who own it at lower levels, congrats, and i think the stock will continue to perform well as the company continues to roll out their new OSM platform.
Another small competitor that maybe worth paying attention to is INUV, a stock i've been buying over the last nine months. INUV just recently pre-announced two weeks ago and expects reveneus to jump 52% YoY to just over $14 million and a 23% increase secquentially. They've got a new management team in place and all the insiders continue to buy stock.
With $51 million in TTM revenues, INUV is currently trading at just 0.6 times price/sales, so if ICLK is undervalued 1.6 times price/sales and going higher, INUV may really be cheap (relative to the group).
And if we apply a 2.6x multiple, it puts INUV at around $1.50 per share.
Good luck.
INUV - Turnaround Complete
I recently attended the INUV presentation at Craig Hallum's Alpha Select conference in NYC two weeks ago and just wanted to let the public know that i think this new management team is really handling themselves well, and starting to execute.
The webcast is worth listening to (http://inuvo.com/investor-relations).
CEO Howe and his new management team are IMHO making all the right moves, disposing of non-core assets and right sizing the business. Revenue growth looks to be accelerating, profit margins continue to expand and the company’s EBTIDA remains positive (and should improve as the revenues tick up). All while the company continues to repay over $2 million in debt from its own cash flows during the first six months of 2009, with additional debt repayments each and every month.
At $.36 per share, INUV’s market cap is currently just $30 million with an enterprise value of just $34 million, and trading at just 0.6 times price/sales as compared to VCLK, which has a 2.7 times price/sales ratio and ICLK, which trades at 1.6 times price/sales, so INUV appears to be undervalued at these levels.
No surprise than to see INUV’s entire management team decide in March 2010 to voluntarily take anywhere from 20% to 40% of their weekly pay in the form of INUV stock, and have been ever since. If that’s not a vote of confidence, I don’t know what is.
To boot, management and the Board of Directors have also personally invested $1.7 million back in December 2009, as part of a $4.2 million institutional equity raise at $0.25 per share and no warrant coverage. The company’s largest investor is also the founder and former CEO of ACXM, which is one of the more successful data analytics companies in the country. And if I didn’t know better, I’d say that the Mr. Morgan and the INUV team could be planning to build the next AXCM.
So for the last year, insiders continue to put their money where their mouth is an own the stock (and right hear at these levels).
After many failed attempts, I believe INUV now has the right management team and very smart money behind the company.
INUV could be a big winner.